Brook Byers is Chairman of the Board of Directors of the OptiMedica® Corporation. He has been closely involved with more than 40 new technology ventures. In 1984, he formed the first Life Sciences venture capital group and led Kleiner, Perkins, Caufield & Byers (KPCB) to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 90 Life Sciences companies which have developed hundreds of products to treat major underserved medical needs.

Mr. Byers is currently on the Board of Directors of eight additional companies, including CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, Nanofluidics and XDx, Inc.. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Ligand Pharmaceuticals (Chairman), Hybritech (Chairman), Genprobe, Nanogen, and others. These companies have pioneered the medical uses of molecular biology, monoclonal antibodies, molecular diagnostics and genomics.

Mr. Byers is currently a Board member of the University of California at San Francisco Medical Foundation, the California Healthcare Institute, the New Schools Foundation, Stanford's Bio-X Advisory Council, the Stanford Eye Council, and TechNet. He is Co-Chair of the current five year, $1.4 billion, UCSF Capital Campaign and was formerly a Director of the Entrepreneurs Foundation, the Asian Art Museum in San Francisco, the Stanford Graduate School of Business Advisory Council, That Man May See (UCSF) Vision Research Foundation (Chairman), and the Georgia Tech Advisory Board. Raised in Atlanta, Georgia, Brook graduated with a B.S.E.E. from Georgia Tech and an M.B.A. from Stanford.

Craig Taylor, a member of the OptiMedica Board of Directors, has been an active venture capitalist since 1977. Specializing in the heathcare industry, he has served as a director for a number of publicly traded companies, including Adeza Biomedical, Pharmacyclics, and Solexa. He also serves as a director for several privately held companies, including ForteBio, Galileo Pharmaceuticals, K2 Optronics, Labcyte, and Zyomyx.

Mr. Taylor was a member of the Board of Directors of the National Venture Capital Association. He currently serves on the Board of Advisors of the MIT/Stanford Venture Laboratory. Before becoming a venture capitalist, he worked in the Office of Technology Licensing at Stanford University. He earned a B.Sc. and an M.S. in physics from Brown University, and an M.B.A. from Stanford University.

Dr. Mark Blumenkranz is a member of the Board of Directors of the OptiMedica Corporation. Recognized as a leading authority in ophthalmology, he is currently Professor and Chairman of the Department of Ophthalmology at Stanford University. He also is an associate examiner for the American Board of Ophthalmology and a member of the Retina, Vitreous, Macula, and Gonin Societies.

Dr. Blumenkranz has served on the Editorial Boards of a number of key industry journals, including: Retina, Graefe's Archives for Ophthalmology, and Ophthalmology. He has received numerous awards, among them the Research to Prevent Blindness Special Manpower Award, the Heed Award, the Rosenthal Award in Visual Sciences, and the American Academy of Ophthalmology Senior Honor Award. Dr. Blumenkranz has served as a Principal Investigator on a number of clinical research trials at Stanford evaluating the effects of laser and pharmacological agents on eye disease. He also has authored more than 100 peer-reviewed publications and book chapters in the area of vitreoretinal surgery, with special interests in surgical adjuvant pharmacology and new microsurgical and laser techniques, and is an inventor on 13 patents.

Dr. Blumenkranz has a longstanding interest in technology transfer and has, over the past 10 years, served on the board of directors and scientific advisory boards of a number of private and publicly-held ophthalmic device and drug companies including OIS, MidLabs and most recently Oculex where he served as Chairman of the SAB and principal trial designer for the Posurdex Study. He was a founding member of the SAB of Eyetech Pharmaceuticals. Dr. Blumenkranz received his B.A, M.S., and M.D. degrees from Brown University.

Thomas Brunner, a member of the Board of Directors, is President and CEO of the Glaucoma Research Foundation. Previously he was Vice-President of the Ophthalmic Business Unit of Coherent, Inc.

Prior to that, Mr. Brunner held a variety of management positions in the Coherent Medical Group. He has more than 30 years experience in the medical laser industry and, in addition to twenty-three years with Coherent, served as the Vice-President Marketing and Sales for Cooper LaserSonics and as the President & C.E.O. of Laserscope before rejoining Coherent. Mr. Brunner is on the Board of the American Society for Laser Medicine and Surgery and he has served as its Treasurer since 1987. He received a B.S.E.E. from Lehigh University and an M.B.A. from the University of Delaware.

Mark J. Forchette, President and Chief Executive Officer, has twenty-three years experience in ophthalmic sales, marketing, and business unit management. Immediately prior to OptiMedica, he served as Vice President of Global Marketing and Sales for the Alcon vitreoretinal business unit. In this position, he led the vitreoretinal unit through a period of substantial portfolio enhancement, infrastructure development, and significant market share increase.

Prior to Alcon, Mr. Forchette was Vice President of Sales and Marketing at Grieshaber & Co. Inc., where he led the privately-held Swiss company's domestic operations through major infrastructure and revenue expansion. Grieshaber, which was acquired by Alcon in 1998, remains a significant contributor to Alcon's successful vitreoretinal portfolio of products. Mr. Forchette received a B.S. in Marketing from Auburn University and completed the Harvard Program for Management Development.

Sallie Shuping-Russell has been active in venture capital since 1983, when she was a consultant at Cambridge Associates in Boston. Later, from 1986-2001, she led Duke University endowment's investments in venture capital, leveraged buyouts, and energy. The performance of Duke's private investment portfolio ranked consistently among the top five of university endowments. Ms. Shuping-Russell was also a founder of Duke Management Company, now DUMAC, and served as its vice president.

From 2001-2004 Ms. Shuping-Russell was a general partner at Intersouth Partners. There she focused primarily on life science companies and was on the Boards of Encelle Pharmaceuticals, Norak Biosciences, and Cogent Neuroscience. In 2004 Ms. Shuping-Russell joined the Quellos Group to help build its private equity program. Quellos was acquired by BlackRock in 2007. She currently is a Managing Director at BlackRock, in its Private Equity Partners group, which manages over $6 billion in assets. In addition to OptiMedica, Ms. Shuping-Russell is on the Boards of Medivance in Denver and PharmatrophiX in Palo Alto.

Ms. Shuping-Russell is a Trustee of the University of North Carolina at Chapel Hill, where she chairs the Audit and Finance Committee. She is also a Director of the University's Investment Fund and a member of UNC's Innovation Circle. She was formerly on the Boards of UNC Healthcare System and the NC Biotechnology Center. Ms. Shuping-Russell holds a BA degree in English and political science from the University of North Carolina and an MBA in finance and economics from Columbia University.